SUZHOU, China and MÖLNDAL, Sweden, Oct. 7, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a...
Hence then, the article about ribo submits european clinical trial application for phase study of inhbe targeting sirna rbd3133 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133 )
Also on site :
- Melania Trump’s Advisor Shades Tom Cruise’s ‘Digger’ After Box Office Bomb — Even Though ‘Melania’ Doc Also Flopped in Theaters
- Disney Cruise Line Offers First Look Inside Disney Believe with New Frozen Dining, Encanto Show, and Themed Lounges
- Tom DeLonge Was in the Crowd When 43,000 Fans Serenaded Him With His Own Song: ‘He Was Definitely in His Feels’